Three Times Daily Antibiotic Eye Drops for Bacterial Conjunctivitis
Yes, besifloxacin 0.6% ophthalmic suspension is FDA-approved and specifically studied for three-times-daily dosing in bacterial conjunctivitis, making it the most appropriate choice for this regimen.
Primary Recommendation
For uncomplicated bacterial conjunctivitis in adults without corneal involvement or contact lens use, besifloxacin 0.6% ophthalmic suspension dosed three times daily for 5-7 days is the evidence-based option 1, 2, 3. This is the only fluoroquinolone specifically developed for topical ophthalmic use and has demonstrated superior efficacy compared to vehicle control with clinical resolution rates of 73.3% versus 43.1% (P < 0.001) 3.
Alternative Options
While the following fluoroquinolones are FDA-approved for bacterial conjunctivitis, they are typically dosed more frequently 4:
- Levofloxacin ophthalmic solution
- Gatifloxacin ophthalmic solution
- Moxifloxacin ophthalmic solution
- Ciprofloxacin ophthalmic solution
- Ofloxacin ophthalmic solution
These agents generally require four-times-daily dosing for optimal efficacy in conjunctivitis, though off-label three-times-daily regimens are sometimes used in clinical practice.
Key Clinical Considerations
Besifloxacin's advantages for TID dosing:
- Specifically designed as a chloro-fluoroquinolone with balanced dual-targeting of bacterial topoisomerase IV and DNA gyrase 5
- Achieves high tear concentrations (mean 610 μg/mL at 10 minutes) with sustained levels >1.6 μg/g for 24 hours 6
- Minimal systemic absorption (Cmax <0.5 ng/mL) 6
- Non-inferior to moxifloxacin 0.5% with similar clinical resolution (58.3% vs 59.4%) and microbial eradication rates (93.3% vs 91.1%) 2
Safety profile: The most common adverse events with besifloxacin TID dosing are mild and include eye pain (10.5%), blurred vision (10.5%), and eye irritation (7.4%) 3. Notably, besifloxacin caused significantly less eye irritation than moxifloxacin (0.3% vs 1.4%, P = 0.0201) 2.
Important Caveats
This recommendation applies specifically to:
- Uncomplicated bacterial conjunctivitis (mucopurulent discharge, matted eyelids)
- No corneal involvement (no keratitis)
- No contact lens use
- No severe pain or vision loss
- No recent ocular surgery
When NOT to use this approach: If bacterial keratitis is present, the guidelines are entirely different. For central or severe keratitis, loading doses every 5-15 minutes followed by hourly applications are required, not three-times-daily dosing 7. The evidence provided focuses heavily on keratitis [8-7], which requires much more aggressive treatment than simple conjunctivitis.
Practical Algorithm
- Confirm diagnosis: Mucopurulent discharge + matted eyelids on awakening + conjunctival injection without corneal involvement
- First-line: Besifloxacin 0.6% suspension, one drop TID for 7 days
- Alternative if besifloxacin unavailable: Consider other fluoroquinolones at their standard (typically QID) dosing
- Consider observation: For mild cases in compliant patients, watchful waiting is reasonable as bacterial conjunctivitis is often self-limited 9, 10
The evidence strongly supports that delayed antibiotic prescribing has similar symptom control to immediate prescribing 9, but when antibiotics are chosen, besifloxacin's proven TID efficacy makes it the optimal selection for this specific dosing schedule.